Intensity Therapeutics, Inc. Awarded Cooperative Research and Development Agreement from the National Cancer Institute

Research program will use Intensity’s in situ chemovaccination technology May 28, 2014 Intensity Therapeutics, Inc. (private) announced today that the Company established a cooperative research and development agreement (CRADA), with the National Institute of Health’s National Cancer Institute (NCI) Vaccine Branch. Intensity Therapeutics was awarded the CRADA by the NCI to study the efficacy and mechanism of action of Intensity’s in situchemovaccination products using in …